Trial Profile
Open-Label Study of Bevacizumab (Avastin®) and Taxane Monotherapy for the First-Line Treatment of Patients With Advanced Triple Negative Breast Cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Docetaxel; Paclitaxel
- Indications Adenocarcinoma; Advanced breast cancer
- Focus Therapeutic Use
- Acronyms BATMAN
- Sponsors Roche
- 31 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Aug 2015 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 11 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.